Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
GW Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 10
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Mentor Capital Invests USD1 Million in GW Pharma 12
Partnerships 13
GW Pharma Enters into Research Agreement with New South Wales 13
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14
Licensing Agreements 15
GW Pharma Terminates License Agreement With Novartis Pharma 15
Equity Offering 17
GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 17
GW Pharma Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of ADSs for USD206 Million 19
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 21
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 23
GW Pharma Announces Partial Exercise Of Underwriter’s Option Of American Depository Shares For US$33 Million 25
Acquisition 27
GW Pharma May Sell Itself 27
GW Pharmaceuticals Plc – Key Competitors 28
GW Pharmaceuticals Plc – Key Employees 29
GW Pharmaceuticals Plc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results 31
May 09, 2017: GW Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress 33
Feb 07, 2017: GW Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Progress 35
Dec 05, 2016: GW Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress 36
Aug 09, 2016: GW Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Progress 37
May 05, 2016: GW Pharmaceuticals Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress 38
Feb 10, 2016: GW Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Progress 39
Corporate Communications 40
May 15, 2017: GW Pharmaceuticals Announces Research & Development Management Appointments 40
Mar 07, 2017: GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Director – UK 41
Government and Public Interest 42
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 42
Product News 43
02/25/2016: Edison Issues ADR Update on GW Pharmaceuticals 43
01/20/2016: State Health Department Announces Compassionate Use Studies of Cannabidiol for Children and Young Adults With Treatment-resistant Epilepsy 44
Product Approvals 45
Apr 21, 2016: GW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Tuberous Sclerosis Complex 45
Clinical Trials 46
Sep 26, 2016: GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 46
Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 48
Jun 21, 2016: GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS) 50
Apr 11, 2016: GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex 51
Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol) 52
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GW Pharmaceuticals Plc, Deals By Therapy Area, 2011 to YTD 2017 9
GW Pharmaceuticals Plc, Medical Devices Deals, 2011 to YTD 2017 10
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Mentor Capital Invests USD1 Million in GW Pharma 12
GW Pharma Enters into Research Agreement with New South Wales 13
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 14
GW Pharma Terminates License Agreement With Novartis Pharma 15
GW Pharma Raises USD290 Million in Public Offering of American Depositary Shares 17
GW Pharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD206 Million 19
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 21
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 23
GW Pharma Announces Partial Exercise Of Underwriter’s Option Of American Depository Shares For US$33 Million 25
GW Pharma May Sell Itself 27
GW Pharmaceuticals Plc, Key Competitors 28
GW Pharmaceuticals Plc, Key Employees 29
GW Pharmaceuticals Plc, Other Locations 30
GW Pharmaceuticals Plc, Subsidiaries 30